Clinical Trials Browser

Phase 2 × PD-1 Antibody × tislelizumab × Clear all

NCT05461235 2022-07-18

Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma

Phase 2 Unknown

Gastrointestinal

PD-1 Antibody